WuXi PharmaTech. received an award from BASF for excellent service and outstanding contributions in the area of custom synthesis for new crop-protection active ingredients.

WuXi PharmaTech. received an award from BASF for excellent service and outstanding contributions in the area of custom synthesis for new crop-protection active ingredients.

Schering-Plough announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.

TU Dortmund is among the winners of the Bio.NRW competition staged by the North Rhine Westphalia Ministry of Innovation, taking €540,000 of a €843,000 project to develop new biocatalysis technologies. The research will be carried out jointly with the Jülich Research Centre.

http://bulletin.sciencebusiness.net/ebulletins/showissue.php3?page=/548/art/14329&ch=2

Scientists have developed a new neuropsychological memory test that could uncover how Parkinson's disease can alter people's ability to learn about the consequences of the choices they make.

Two prestigious universities - Oxford in Britain and McGill in Canada - have joined hands for research on the human brain. The two universities are among world leaders in neuroscience research.

In the next four years the European Commission will be providing funding to the tune of €6 million for the new "PolyModE" research project, which is being coordinated at the University of Münster.

http://www.innovations-report.com/html/reports/life_sciences/european_commission_fund_research_project_wwu_takes_135281.html

Doctors at Fremantle Hospital are pioneering new technology which gives a 3-D view of a patient’s heart in a simple 20-minute procedure.

http://www.thewest.com.au/default.aspx?MenuID=158&ContentID=152917

A treatment for men with early prostate cancer but with much milder side effects than existing therapy has been discovered by British scientists.

The procedure uses ultrasound to 'melt' tumours instead of putting patients through surgery or radiotherapy which damage healthy cells around the gland.

Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the Ministry of Health, Labor and Welfare (MHLW) approval to market the FACIL™ and REPLY™ families of dual and single chamber rate responsive pacemakers.

NorDiag has fully automated the process from sample preparation of different clinical samples to the set up of the downstream amplification technologies. NorDiag's "Bullet" instrument has the capacity to process up to 100,000 isolations per year. The clinical trial has been executed at synlab,Weiden, Germany.

http://www.silobreaker.com/nordiag-successful-completion-of-clinical-trial-for-nordiags-new-bullet-bugsn-beadstm-kit-5_2262432690273779746

Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) invites investors, analysts, media and other interested parties to attend its annual R&D day on Thursday, July 16, 2009 in Geneva, Switzerland.

Pall Life Sciences, a top supplier of filtration, separation and purification devices, has received the 2008 Supplier of the Year Award from the European segment of VWR for its commitment to helping VWR provide quality products and services to Europe’s research laboratories.

India-based pharmaceutical company, Orchid Chemicals and Pharmaceuticals has recieved approval from the US Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Amlodipine Besylate tablets.

http://www.biospectrumasia.com/content/030709IND9874.asp

Roche NimbleGen, supplier of a proprietary suite of DNA microarrays has entered into a partnership with the Korea Centers for Disease Control and Prevention (KCDC) and Macrogen, to conduct an eight-month intensive Copy Number Variation (CNV) study of Korean individuals.

People who live alone in middle age face nearly double the risk of developing cognitive problems in later life compared with married or cohabiting counterparts, according to a new study.

People who live on vegetarian diets have slightly weaker bones than their meat-eating counterparts, according to a joint Australian-Vietnamese study of links between the bones and diet of more than 2700 people.

Imperial Innovations (AIM: IVO, "Imperial Innovations"), a leading technology commercialisation and investment company, has increased its stake in OSspray, an emerging speciality dental company, following a further drawdown of £980,000 under its existing funding arrangements.

Clavis Pharma ASA (OSE: CLAVIS) announces today that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Intravenous CP-4126. Intravenous CP-4126 is in development as a new, first-line treatment for pancreatic cancer and the phase II program has already been initiated in Europe.

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure™ emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks. The objectives were to evaluate the tolerability, pharmacokinetics, and efficacy of the topical treatment.

http://www.biotech-intelligence.com/html/html/pool_7/35a3ed7580dacdfaf5c98616b86997be.html